Breast Cancer

Concurrent use of trastuzumab and chemotherapy significantly reduces recurrence

Published in Women's Health Weekly, June 9th, 2005

A study led by a Mayo Clinic researcher in Jacksonville, Florida, and conducted by the North Central Cancer Treatment Group (NCCTG) has provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and the monoclonal antibody trastuzumab (Herceptin).

According to Mayo Clinic medical oncologist and NCCTG study chair Edith Perez, MD, these results could change the standard of care for thousands of women with breast cancer.

"Women with HER-2 positive breast cancer had a high risk of the cancer returning and of dying from breast cancer. This intervention - chemotherapy plus trastuzumab - essentially...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry